News and Events

4TEEN4’s first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis

4TEEN4 Pharmaceuticals GmbH ("4TEEN4") announces data on the efficacy of its lead product, Procizumab, that promptly restored cardiac dysfunction in a preclinical sepsis model by inhibiting the cardiac depressant factor DPP3. The current findings indicate that DPP3 plays an important role in septic cardiomyopathy. Sepsis is a dysregulated host response to an infection that ultimately leads to organ dysfunction.

READ MORE ↵


The Cardiac Depressant Factor DPP3 is Predicting Organ Failure in Burn Patients

Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.

READ MORE ↵


Biotech Startup 4TEEN4 Pharmaceuicals Closes EUR 7 Million Series A Financing

Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.

READ MORE ↵


4TEEN4 Pharmaceuticals reports first results on Procizumab, a novel therapeutic anti-DPP3 antibody for treatment of acute myocardial depression.

4TEEN4 Pharmaceuticals GmbH today for the first time reported preclinical data on its lead product Procizumab, a therapeutic antibody targeting circulating Dipeptidyl Peptidase 3 (DPP3) for the treatment of patients with acute myocardial depression including acute heart failure and cardiogenic shock.

READ MORE ↵